CDMO

Aterian Investment Partners to Recapitalize CPL, a Leading Pharmaceutical Contract Development and Manufacturing Organization

Retrieved on: 
Monday, April 1, 2024
Other Manufacturing, Finance, Banking, Professional Services, Manufacturing, Biotechnology, Health, Pharmaceutical, General Health, CDMO, Partnership, Patient, History, Health Canada, Goodmans, Investment, European, Multimedia, FDA, Kirkland & Ellis, Pharmaceutical industry

Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.

Key Points: 
  • Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize Contract Pharmaceuticals Limited Canada ("CPL" or the “Company”), a leading North American contract development and manufacturing organization (CDMO) of non-sterile liquid and semi-solid dosage forms.
  • View the full release here: https://www.businesswire.com/news/home/20240401893587/en/
    CPL, based in Mississauga, Ontario, Canada, is an industry leader with longstanding relationships with 15 of the top 20 global pharmaceutical companies.
  • Further, CPL has a tremendous heritage of premier expertise and capabilities to offer customers a one-stop shop for all their development, manufacturing, packaging, and testing needs.
  • We look forward to working alongside CPL’s stakeholders on the Company’s next stage of growth.”
    Kirkland & Ellis LLP, and Osler, Hoskin & Harcourt LLP advised Aterian.

KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer

Retrieved on: 
Monday, April 1, 2024
Other Manufacturing, Research, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, CDMO, Novartis, Regulatory affairs, CGMP, Bayer, KBI, Chemical engineering, Multimedia, Amgen, Rensselaer Polytechnic Institute, Engineering

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.

Key Points: 
  • KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
  • Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
  • "We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D.
  • "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers.

Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report

Retrieved on: 
Wednesday, March 27, 2024
Medical Supplies, Biotechnology, Manufacturing, Professional Services, Health, General Health, Pharmaceutical, Environmental, Social and Governance (ESG), Transport, Logistics, Supply Chain Management, Packaging, Carbon, Element, Carbon footprint, Culture, CDMO, Waste management, Organization, Consciousness, Learning, Biophysical environment, Recycling, ESG, Science, Human, Woman, Social, PCI, Safety, Water, Supplier, Multimedia, DEI, Management

PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report .

Key Points: 
  • PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report .
  • View the full release here: https://www.businesswire.com/news/home/20240327397711/en/
    The report discloses PCI's performance, targets, and strategy to achieve nine identified impact categories.
  • Other highlights from PCI’s ESG report include:
    Carbon footprint targets and strategy were developed in alignment to Science Based Targets.
  • “Although we at PCI formally established our ESG Program in 2021, our ESG consciousness is by no means new,” said Salim Haffar, CEO of PCI Pharma Services.

Christi Shaw, Former CEO of Kite, a Gilead Company, Appointed to Cellares Advisory Board to Advance Cell Therapy Manufacturing

Retrieved on: 
Tuesday, March 26, 2024
Health, Stem Cells, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Automation, CDMO, Bone marrow, Advisory board, Novartis, Patient, Research, Multiple myeloma, Cancer, Kite Pharma, Johnson & Johnson, Workforce, Lilly, Pharmaceutical industry

Cellares , a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization (IDMO), today announced the addition of Christi Shaw to its Advisory Board.

Key Points: 
  • Cellares , a leader in the automation of cell therapy manufacturing and the world’s first Integrated Development and Manufacturing Organization (IDMO), today announced the addition of Christi Shaw to its Advisory Board.
  • She formerly served as Chief Executive Officer of Kite, a Gilead Company, where she led a global team dedicated exclusively to the research, commercialization, and manufacturing of cell therapy.
  • In response to her new role, Ms. Shaw stated, "Joining Cellares' Advisory Board presents an exciting opportunity to contribute to the expansion and advancement of cell therapy manufacturing.
  • I look forward to working with Cellares to address these challenges, with the ultimate goal of improving patient access to cell therapies."

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report 2024: Rapid Expansion Fueled by API Complexity and Cost Reduction Needs - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Pharmaceutical, Automation, CDMO, Organization, Growth, Application, Drug, COVID-19, Patient, Workflow, Research, Investment, API, Patent, FDA, Developed country, Fine chemical

The "Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing pharmaceutical R&D investments, patent expirations, and a rise in demand for generic drugs and biologic innovations propelling outsourcing are the factors driving the market.
  • The growth of small molecules, rising active pharmaceutical ingredient (API) complexity and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector.
  • Only a few companies have achieved global reach and scale in the contract development and manufacturing organization (CDMO) sector, which is still fragmented.

Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Chemicals, Plastics, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Catalent, CDMO, Growth, Prevalence, Cardiovascular disease, A-DNA, Application, COVID-19, Patient, Conditional sentence, Samsung Biologics, Research, Diabetes, Messenger, WuXi Biologics, Investment, Antibody, Drug development, Workforce, API, Glaucoma, Vaccine, CMOS, Fine chemical

The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.

Key Points: 
  • The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.
  • The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand.
  • CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey.
  • The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle.

Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine

Retrieved on: 
Thursday, March 21, 2024
Research, Medical Devices, Genetics, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Medical school, B cell, CDMO, NUS, CRL, DNA, Tecmar, HQ, National university, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.
  • NUS Medicine will leverage this collaboration to access Charles River’s center of excellence, and established manufacturing platform, eXpDNA™.
  • In recent years, Charles River has significantly expanded its cell and gene therapy portfolio to streamline complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing capabilities, Charles River offers an industry-leading “concept to cure” advanced therapeutic solution.

Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services

Retrieved on: 
Monday, March 18, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Chemicals, Plastics, Manufacturing, CDMO, Conference, Business, Drug delivery, University, Curriculum, Multimedia

Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit .

Key Points: 
  • Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today welcomes Jennifer Riter as Vice President of Analytical Services to head up the recently announced analytical services global business unit .
  • View the full release here: https://www.businesswire.com/news/home/20240318401921/en/
    Jennifer Riter joins Kindeva Drug Delivery as Vice President of Analytical Services to lead new analytical services business unit.
  • She brings specific leadership and expertise in analytical testing which includes extractables and leachables, container closure integrity and device/combination product performance, and particle analysis.
  • “Kindeva’s expertise in all areas of drug delivery and manufacturing is unmatched in the industry,” Riter said.

Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

Retrieved on: 
Thursday, March 14, 2024
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Erythromelalgia, AAV, Diabetic neuropathy, CDMO, Patient, CRL, Good manufacturing practice, Gene, DNA, CAP, Chronic pain, Doctor of Philosophy, GMP, Navega, Therapy, Peripheral neuropathy, CGT, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement.
  • As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I clinical trials.
  • To bring NT-Z001 to clinic, Navega will leverage Charles River’s off-the-shelf plasmid products, custom plasmid capabilities, and Good Manufacturing Practice (GMP)-grade AAV production.
  • Join Ana Moreno, CEO, Navega Therapeutics on March 19 in San Francisco – see the full agenda and save your seat: https://bit.ly/3SW3VOV
    “The collaboration with Navega will tap into our premier gene therapy CDMO capabilities and robust AAV offerings.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Avid Bioservices, Inc. (CDMO) on Behalf of Investors

Retrieved on: 
Thursday, March 14, 2024
Class Action Lawsuit, Professional Services, Legal, Debt-to-GDP ratio, GPM, CDMO, News, Person, Acceleration, Security (finance)

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ) investors concerning the Company’s possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Avid Bioservices, Inc. (“Avid” or the “Company”) (NASDAQ: CDMO ) investors concerning the Company’s possible violations of the federal securities laws.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On March 6, 2024, Avid disclosed that it had received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026.
  • Whistleblower Notice: Persons with non-public information regarding Avid should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.